Hims & Hers’ 458% Rally Tested as FDA Undercuts Obesity Sales
The blistering rally in Hims & Hers Health Inc. that’s captivated meme-stock traders has ground to a halt, setting up a ...
Hims & Hers Declines - How The GLP-1 Market Shift Affects Growth
Hims & Hers plans to launch a generic version of liraglutide, but its efficacy is significantly lower than semaglutide. See ...
HIMS Earnings Preview: Will The Stock Rebound After 25% Drop?
Hims & Hers Health (NYSE:HIMS) is set to report its earnings on Monday, Feb 24 after market close. HIMS stock plunged over 25 ...
Ozempic, Wegovy maker calls out Hims & Hers Super Bowl ad: ‘Check before you inject’
Compounded weight-loss medications, such as those promoted in the Hims & Hers commercial, aren’t approved by the Food and ...
Why Is HIMS Stock Dropping Today?
The U.S. FDA has officially declared that Novo Nordisk’s (NVO) popular diabetes and weight loss therapies, Ozempic and Wegovy ...
Stocktwits on MSN10h
Hims & Hers Retail Traders Eye Robust Post-Earnings Rebound Following Stock’s Worst Drop On Semaglutide Update
Hims & Hers Health Inc. (HIMS) stock tumbled over 25% on Friday, extending losses in after-hours trading after the U.S. Food ...
Hims & Hers plunges as the FDA says Novo’s weight loss drugs are not in shortage
Hims & Hers Health (HIMS) stock falls as the FDA declares that Novo Nordisk's (NVO) weight loss therapies are no longer in ...
24/7 Wall St. on MSN3d
Hims & Hers (HIMS) Down 21% – Is the GLP-1 Gravy Train Over?
Shares of Hims & Hers Health (NYSE:HIMS) are down about 21%, or $14. All on news the Ozempic shortage is over. Key Points ...